CRO Service & Digital: Integrated Solutions for Modern Drug Development
Product Introduction
In the era of digital transformation in pharmaceuticals, our CRO Service & Digital offerings fuse traditional contract research expertise with cutting-edge technologies to revolutionize drug development. As a comprehensive CRO division, we provide end-to-end clinical research support—from trial design to regulatory submission—enhanced by AI, blockchain, and cloud-based platforms for unprecedented efficiency and data integrity. Tailored for biopharma innovators, our services cover full lifecycle management, with a strong emphasis on oncology, rare diseases, and advanced therapies. Compliant with ICH-GCP, FDA, EMA, and NMPA standards, we leverage digital tools like EDC systems, AI patient matching, and real-time analytics to reduce timelines by 30%, cut costs, and ensure traceable, patient-centric outcomes—empowering you to navigate complex trials and accelerate market entry in a data-driven world.
Key Advantages & Features
Our CRO services integrate seamlessly with digital innovations for superior performance and adaptability. Key highlights include:
|
Advantage/Feature |
Description |
|
Digital-Enabled Efficiency |
AI-driven patient recruitment and EDC platforms shorten trial cycles by 30-50%, with blockchain ensuring 100% data security and audit trails compliant with GDPR/HIPAA. |
|
Expert Multidisciplinary Teams |
Seasoned professionals (e.g., oncologists, biostatisticians) with 15+ years of experience, delivering 99.8% on-time milestones across 50+ global projects. |
|
Modular & Scalable Solutions |
Flexible modules from single-phase support to full-spectrum trials, with hybrid models saving 20-25% on costs for China-to-global expansions. |
|
Advanced Risk Mitigation |
Real-time monitoring via IoT dashboards and CAPA frameworks, achieving zero major deviations in recent FDA/EMA inspections. |
|
Oncology & Precision Focus |
Specialized tools for biomarker analysis and adaptive designs, boosting enrollment in heterogeneous populations by 40-55%. |
|
End-to-End Compliance |
Integrated PV, RA, and data services with eCTD authoring and signal detection, streamlining submissions and post-market surveillance. |
Product Types
Our CRO Service & Digital portfolio is structured into specialized categories, blending human expertise with digital prowess:
Clinical Trial Management
Full lifecycle oversight, including protocol design, site activation, and adaptive monitoring with AI-enhanced recruitment.
Data Management & Biostatistics
EDC-integrated cleaning, CDISC-compliant analysis, and AI-powered statistical modeling for robust TLFs and interim reads.
Pharmacovigilance & Safety
24/7 ICSR processing, AI signal detection, and RMP development using Argus databases for proactive risk management.
Regulatory Affairs Consulting
eCTD dossier preparation, gap analyses, and agency liaison with digital intelligence platforms for harmonized global filings.
Oncology Clinical Trials
Biomarker-driven basket/umbrella studies, with decentralized platforms for precision oncology endpoints like RECIST and OS.
Digital Tools & Platforms
Standalone AI patient matching, blockchain data vaults, and cloud analytics for enhanced trial feasibility and RWE generation.
Product Applications
Our services apply across diverse therapeutic and operational needs, leveraging digital integration for real-world impact:
Oncology & Immunotherapies: Adaptive trials for CAR-T and checkpoint inhibitors, using NGS integrations for biomarker-enriched cohorts and rapid efficacy reads.
Rare Diseases & Gene Therapies: Precision recruitment via AI matching for orphan indications, with PV support for long-term safety in small populations.
Biologics & Vaccines: End-to-end data handling for multi-center studies, including decentralized monitoring to accelerate Phase III confirmatory trials.
Regulatory & Market Access: Parallel filings for NMPA/FDA/EMA, with digital RMPs to secure breakthrough designations and conditional approvals.
Post-Market Surveillance: Lifecycle PV for commercial products, incorporating RWE from wearables and social media for ongoing benefit-risk assessments.
Global Expansion: Hybrid CRO models for China-based sponsors entering Western markets, optimizing costs and compliance in cross-border trials.